

Total Voting Rights

RNS Number : 02111
GCP Infrastructure Investments Ltd
31 March 2020

GCP Infrastructure Investments Limited
("GCP Infra" or the "Company")
LEI: 213800W64MNATSIV5Z47

Total Voting Rights

31 March 2020

In conformity with the FCA's Disclosure Guidance and Transparency Rules, GCP Infra, the only UK listed fund focused primarily on investments in UK infrastructure debt, would like to notify the market of the following:

As at 31 March 2020, the Company's issued share capital consists of 878,368,489 Ordinary shares of £0.01 each with voting rights.

The above figure of 878,368,489 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, GCP Infra, under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

Gravis Capital Management Limited
Philip Kent
Dion Di Miceli

+44 (0)20 3405 8500

Stifel Nicolaus Europe Limited
Mark Bloomfield
Nick Donovan

+44 (0)20 7710 7600

Buchanan/Quill
Helen Tarbet
Sarah Gibbons-Cook
Henry Wilson

+44 (0)20 7466 5000

Notes to the Editor

About GCP Infra

GCP Infra is a closed-ended investment company and FTSE-250 constituent whose shares are traded on the main market of the London Stock Exchange. Its objective is to provide shareholders with regular, sustained, long-term distributions and to preserve capital over the long term by generating exposure to UK infrastructure debt and related and/or similar assets. The Company primarily targets investments in infrastructure projects with long term, public sector-backed, availability-based revenues. Where possible, investments are structured to benefit from partial inflation protection. GCP Infra is advised by Gravis Capital Management Limited.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lse.com or visit www.rns.com.

END

TVRBUGDXDGXDGGG